Actionable medical results are often a key component in deciding a patient’s medical management and specialized treatment options. However, some genetic test results can have unclear implications or Variants of Unknown Significance (VUS), which can often affect a clinician’s medical management plans for their patients. During the 2017 ACMG…
Ambry experts and collaborators presented new research at this year’s Annual Meeting on Women’s Cancer. In addition to discussing GYNplus and OvaNext testing options, Ambry featured three scientific posters and a lunch presentation “Advancing Molecular Diagnostics for Gynecologic Cancer: Efforts in Data Sharing and Tumor Testing to Improve…
Colon cancer is the third most common cancer diagnosed in both men and women in the United States, and more than 95,000 new cases of colon cancer and 39,000 new cases of rectal cancer are estimated for 2017, according to the American Cancer Society. Up to 10% of colorectal cancer is hereditary, or caused by inherited gene mutations. Hereditary…
Ribonucleic Acid, otherwise known as RNA, is the messenger that carries instructions for controlling the synthesis of proteins from Deoxyribonucleic Acid (DNA). The central dogma of molecular biology states that “DNA makes RNA makes protein." However, for the proteins, which are the final product, to work properly, the RNA needs to be “edited,"…
Since March 2016, Ambry has been collecting data samples from researchers through the data sharing program AmbryShare, with a goal of improving scientific research aimed at making more tailored treatments and/or cures available to clinicians and their patients. Now anyone can participate in a research study and choose to either submit an e-consent…
In the first of seven dinner series events, on Tuesday, January 31st, Ambry Genetics presented to more than 45 attendees at Spago in Beverly Hills, California. The “AmbrySpeaks Tour—Accuracy and Innovation in the Era of Collaborative Genetics” challenges the common misconception that Next-generation sequencing (NGS) is 100 percent accurate,…
Advances in molecular diagnostics offer clinicians more choices than ever when it comes to disease-targeted genetic testing for their patients.1 However, the amount of options can complicate deciding which test is best for each patient. Next generation sequencing (NGS)-based clinical genetic tests, such as multi-gene panel testing (MGPT), offer…
Ever since our initial publication of Sanger sequencing confirmation was featured in The Journal of Molecular Diagnostics, in addition to our accompanying presentation at the National Society of Genetic Counselors conference last fall, Ambry has been touting our superior scientifically-proven genetic testing. Now we are bringing the message that…
Breast cancer in men may be rare in the average population, but is far more common in people with an underlying genetic predisposition. Finding a cancer gene mutation in a man with breast cancer can drastically impact medical management for him and his family members (who may otherwise not be screened for the disease). Current guidelines recommend…
The Mauli Ola Foundation has announced the winning team of their 3rd annual Battle for the Breasts (B4TB) online surf contest, as of the end of October, which was also Breast Cancer Awareness month. As a proud sponsor of the competition, Ambry would like to congratulate the winning team of professional surfer, Dimity Stoyle of Maroochydore, Queensland,…